Article Versions Notes

Cenariu D, Zimta A-A, Munteanu R, Onaciu A, Moldovan CS, Jurj A, Raduly L, Moldovan A, Florea A, Budisan L, et al. Hsa-miR-125b Therapeutic Role in Colon Cancer Is Dependent on the Mutation Status of the TP53 Gene. Pharmaceutics. 2021; 13(5):664. https://doi.org/10.3390/pharmaceutics13050664

Cenariu, Diana, Alina-Andreea Zimta, Raluca Munteanu, Anca Onaciu, Cristian Silviu Moldovan, Ancuta Jurj, Lajos Raduly, Alin Moldovan, Adrian Florea, Liviuta Budisan, and et al. 2021. "Hsa-miR-125b Therapeutic Role in Colon Cancer Is Dependent on the Mutation Status of the TP53 Gene" Pharmaceutics 13, no. 5: 664. https://doi.org/10.3390/pharmaceutics13050664

Cenariu, D., Zimta, A. -A., Munteanu, R., Onaciu, A., Moldovan, C. S., Jurj, A., Raduly, L., Moldovan, A., Florea, A., Budisan, L., Pop, L. A., Magdo, L., Albu, M. T., Tonea, R. B., Muresan, M. -S., Ionescu, C., Petrut, B., Buiga, R., Irimie, A., ... Berindan-Neagoe, I. (2021). Hsa-miR-125b Therapeutic Role in Colon Cancer Is Dependent on the Mutation Status of the TP53 Gene. Pharmaceutics, 13(5), 664. https://doi.org/10.3390/pharmaceutics13050664